Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 2018

View Archived Issues

Lundbeck initiates phase I study with Lu-AF-28996 for Parkinson's disease

Rigel announces the initiation of phase I trial of R-835

How targeted therapies are lost in translation

Increasing the specificity of kappa-opioid agonists

Dzuveo approved in Europe

FDA grants priority review for glasdegib in previously untreated acute myeloid leukemia

Vamorolone demonstrates improvements in strength and endurance in boys with DMD

First patient dosed in phase II study of REL-1017 in patients with major depressive disorder

FDA grants orphan drug designation for cannabidiol as treatment of autoimmune hepatitis

PharmaMar and Chugai announce early termination of the license agreement for Zepsyre in Japan

Preliminary data from phase Ib/II study of PCM-075 in combination with cytarabine or decitabine

Positive topline data presented from phase II/III study of CR-845

Results presented for KEYNOTE-046 study of ADXS-PSA plus pembrolizumab in patients with mCRPC

Aldeyra announces additional clinical programs planned for next year

Roivant creates new business units and launches Altavant Sciences

Part A data from phase III HOPE study of voxelotor in sickle cell disease show primary endpoint met

MSDC-5514 - a novel insulin sensitizer to treat diabetes and nonalcoholic steatohepatitis

FDA approves Braftovi + Mektovi for unresectable or metastatic melanoma

Omeros obtains approvals to begin phase I trial with PDE7 inhibitor OMS-527

Medivir reports promising topline results from phase IIa extension study of MIV-711

Gachon University, Seoul National University identify SIRT1 activators

Vertex patents CFTR modulators

FDA grants priority review to Jazz's pediatric sNDA for Xyrem

Microtubule-specific brain-penetrating PET imaging agent [11C]HD-800 characterized

ExCellThera completes phase I/II trial of ECT-001 technology in leukemia

Benefits seen with MEDI-0382 in overweight/obese subjects with type 2 diabetes

Alexion seeks E.U. approval for ALXN-1210 for PNH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...